EP1024804A4 - Mtp-inhibitoren und fettlösliche vitamin-therapeutika zur verringerung des serum lipids - Google Patents

Mtp-inhibitoren und fettlösliche vitamin-therapeutika zur verringerung des serum lipids

Info

Publication number
EP1024804A4
EP1024804A4 EP98918680A EP98918680A EP1024804A4 EP 1024804 A4 EP1024804 A4 EP 1024804A4 EP 98918680 A EP98918680 A EP 98918680A EP 98918680 A EP98918680 A EP 98918680A EP 1024804 A4 EP1024804 A4 EP 1024804A4
Authority
EP
European Patent Office
Prior art keywords
soluble vitamin
lipid levels
fat soluble
serum lipid
therapeutic combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98918680A
Other languages
English (en)
French (fr)
Other versions
EP1024804A1 (de
Inventor
Richard E Gregg
John R Ii Wetterau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1024804A1 publication Critical patent/EP1024804A1/de
Publication of EP1024804A4 publication Critical patent/EP1024804A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP98918680A 1997-05-01 1998-04-23 Mtp-inhibitoren und fettlösliche vitamin-therapeutika zur verringerung des serum lipids Withdrawn EP1024804A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4540597P 1997-05-01 1997-05-01
US45405P 1997-05-01
PCT/US1998/008269 WO1998050028A1 (en) 1997-05-01 1998-04-23 Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Publications (2)

Publication Number Publication Date
EP1024804A1 EP1024804A1 (de) 2000-08-09
EP1024804A4 true EP1024804A4 (de) 2001-03-21

Family

ID=21937689

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98918680A Withdrawn EP1024804A4 (de) 1997-05-01 1998-04-23 Mtp-inhibitoren und fettlösliche vitamin-therapeutika zur verringerung des serum lipids

Country Status (5)

Country Link
EP (1) EP1024804A4 (de)
JP (1) JP2001527551A (de)
AU (1) AU748608B2 (de)
CA (1) CA2286341A1 (de)
WO (1) WO1998050028A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19929012A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
FR2845601B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
FR2868313B1 (fr) * 2004-03-31 2008-08-15 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
JP2009511635A (ja) * 2005-10-18 2009-03-19 エージェリオン ファーマシューティカルズ 哺乳動物における高脂血症に関連する障害を治療するための方法
CN103690960A (zh) * 2013-12-18 2014-04-02 北京科源创欣科技有限公司 甲磺酸洛美他派药物组合物及制备方法
AT15657U1 (de) 2016-10-06 2018-04-15 Bioenergy Healthcare GmbH Lipidsenker
EP4188372A1 (de) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapid zur verwendung in verfahren zur behandlung von hyperlipidämie und hypercholesterinämie bei pädiatrischen patienten

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584446A2 (de) * 1992-03-06 1994-03-02 E.R. SQUIBB & SONS, INC. Microsomales Triglyceridtransferprotein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) * 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
JPS5612114B2 (de) * 1974-06-07 1981-03-18
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584446A2 (de) * 1992-03-06 1994-03-02 E.R. SQUIBB & SONS, INC. Microsomales Triglyceridtransferprotein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9850028A1 *

Also Published As

Publication number Publication date
WO1998050028A1 (en) 1998-11-12
AU748608B2 (en) 2002-06-06
EP1024804A1 (de) 2000-08-09
CA2286341A1 (en) 1998-11-12
AU7155998A (en) 1998-11-27
JP2001527551A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
GB2346809B (en) Heel care device and method
IL139321A0 (en) Methods and compositions for modulating lipid metabolism
IL111172A0 (en) Shoes for reducing stress in feet
ID23687A (id) Metode penggunaan penghambat siklooksigenase-2 dalam pencegahan penyakit kardiovaskuler
EP0979647A4 (de) Fettemulsion zur oralen verabreichung
PL334662A1 (en) Terbenzimidazoles (inhibitors of topisomerase) useful in medical therapy
EP1033994A4 (de) Verfahren zur herstellung von bioginkgo
EP1210075A4 (de) Zusammenstellungen und methoden zur veränderung des fettgehalts der haut
IL133929A0 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
ATA159197A (de) Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
PL335402A1 (en) Complementation of proteins in transgenous plants
GB9725946D0 (en) Lipid compositions and their use
ATA6897A (de) Präparation umfassend thiolgruppen-hältige proteine
AU6894298A (en) Human fatty acid binding protein
ZA986047B (en) 6-pyrrolidin-2-ylpyrindines their preparation and their therapeutic application
AU1456899A (en) Human protein kinase and kinase inhibitors
GB9815798D0 (en) Improvements in and relating to casting
TW428769U (en) Joint-portion structure between pedal and heel-plate of foot pedal
IL142069A0 (en) Methods of downmodulating the immune response to therapeutic proteins
GB9718664D0 (en) Improvements in or relating to capsules
GB9719318D0 (en) Improvements in and relating to casting
ZA982766B (en) Dithiolan derivatives their preparation and their therapeutic effect
GB9714509D0 (en) Improvements in and relating to casting
GB9713265D0 (en) Improvements in and relating to casting
NZ328785A (en) Investment risk calculation and presentation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/355 A, 7A 61K 31/34 B, 7A 61K 31/075 B, 7A 61K 31/445 B, 7A 61K 31/495 B, 7A 61K 31/50 B, 7A 61K 45/06 B, 7A 61P 9/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010131

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040827